C4 Therapeutics Inc (CCCC) Hedge Fund Ownership (Q2 2026)

C4 Therapeutics Inc (CCCC)

146 + Investors. Track Smart Money conviction in CCCC. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — CCCC

Based on 147 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added CCCC than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

147 hedge funds hold CCCC right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +47% more funds vs a year ago

fund count last 6Q

+47 new funds entered over the past year (+47% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 66% buying

108 buying56 selling

Last quarter: 108 funds were net buyers (53 opened a brand new position + 55 added to an existing one). Only 56 were sellers (29 trimmed + 27 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+21 vs last Q)

new funds entering per quarter

Funds opening a new CCCC position: 24 → 22 → 32 → 53. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔒

47% of holders stayed for 2+ years

■ 47% conviction (2yr+) ■ 24% medium ■ 29% new

69 out of 147 hedge funds have held CCCC for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💰

Value +157% but shares only +44% — price-driven

Value

+157%

+43%

Last quarter: the total dollar value of institutional holdings rose +157%, but actual share count only changed +44%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

🚀

Acceleration phase — new buyers rushing in

25 → 24 → 22 → 32 → 53 new funds/Q

New funds entering each quarter: 24 → 22 → 32 → 53. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

🏛️

Veteran-anchored — 61% veterans vs 28% newcomers

■ 61% veterans ■ 11% 1-2yr ■ 28% new

Entry-cohort mix of 155 holders: 95 (61%) are 2+ year veterans, 17 entered 1–2 years ago, and 43 (28%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 43% AUM from top-100 funds

43% from top-100 AUM funds

39 of 147 holders are among the 100 largest funds by AUM, controlling 43% of total institutional value in CCCC. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

4.4

out of 10

Moderate Exit Risk

Exit risk score 4.4/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	146	121	20.66%
13F Shares	119M	83M	43.5%
Total Value	$542M	$211M	156.41%
New Positions	52	32	+20
Increased Positions	53	39	+14
Closed Positions	27	12	+15
Reduced Positions	26	31	-5
Total Calls	6	4	50.0%
Total Puts	2	2	-
PUT/CALL Ratio	0.33	0.5	Bullish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

146

121

20.66%

13F Shares

119M

83M

43.5%

Total Value

$542M

$211M

156.41%

New Positions

+20

Increased Positions

+14

Closed Positions

+15

Reduced Positions

-5

Total Calls

50.0%

Total Puts

PUT/CALL Ratio

0.33

0.5

Bullish

Institutional Holders (2026 Q2)

146 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CCCC. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 CCCC holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Squadron Capital Management LLC	10.43%	7,200,000	$33.6M
2	Lynx1 Capital Management LP	6.74%	7,326,691	$34.2M
3	Bain Capital Life Sciences Investors, LLC	1.99%	7,171,910	$33.5M
4	Velan Capital Investment Management LP	1.62%	570,000	$2.7M
5	Silverarc Capital Management, LLC	1.47%	3,032,060	$14.2M
6	HighVista Strategies LLC	1.44%	1,348,136	$6.3M
7	Ikarian Capital, LLC	1.22%	2,433,000	$11.4M
8	Patient Square Capital LP	1.16%	1,608,815	$7.5M
9	Squadron Capital Management LLC	0.58%	400,000	$1.9M
10	Soleus Capital Management, L.P.	0.54%	3,377,981	$15.8M
11	Platinum Investment Management Ltd	0.44%	384,766	$1.8M
12	Stempoint Capital LP	0.42%	523,648	$2.4M
13	Ra Capital Management, L.P.	0.32%	8,000,000	$37.4M
14	Seven Fleet Capital Management LP	0.29%	381,169	$1.8M
15	Intrepid Family Office LLC	0.22%	65,000	$304K
16	Atom Investors LP	0.15%	364,351	$1.7M
17	Palumbo Wealth Management LLC	0.13%	132,417	$618K
18	Wasatch Advisors LP	0.11%	3,522,644	$16.5M
19	Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group	0.10%	85,000	$397K
20	Scientech Research LLC	0.08%	21,260	$99K
21	Headlands Technologies LLC	0.08%	153,972	$719K
22	ADAR1 Capital Management, LLC	0.06%	291,957	$1.4M
23	CV Advisors LLC	0.06%	65,000	$304K
24	Boothbay Fund Management, LLC	0.05%	736,331	$3.4M
25	Candriam S.C.A.	0.04%	1,796,937	$8.4M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — C4 Therapeutics Inc (CCCC)

What does the Smart Money Trend signal show for CCCC?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added CCCC than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CCCC?

More buyers than sellers — 66% buying: Last quarter: 108 funds were net buyers (53 opened a brand new position + 55 added to an existing one). Only 56 were sellers (29 trimmed + 27 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for CCCC holders?

Elite ownership — 43% AUM from top-100 funds: 39 of 147 holders are among the 100 largest funds by AUM, controlling 43% of total institutional value in CCCC. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held CCCC?

47% of holders stayed for 2+ years: 69 out of 147 hedge funds have held CCCC for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

C4 Therapeutics Inc (CCCC)

Smart Money Signals — CCCC

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +47% more funds vs a year ago

More buyers than sellers — 66% buying

More new buyers each quarter (+21 vs last Q)

47% of holders stayed for 2+ years

Value +157% but shares only +44% — price-driven

Acceleration phase — new buyers rushing in

Veteran-anchored — 61% veterans vs 28% newcomers

Elite ownership — 43% AUM from top-100 funds

Institutional Sentiment Summary — CCCC

Hedge Fund Ownership: CCCC

Market Analysis: CCCC

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: CCCC

Hedge Fund Positioning: CCCC

Statistics: CCCC

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — C4 Therapeutics Inc (CCCC)

Welcome to 13Foresight!